ebola
crisi
occur
westafrica
highlight
urgenc
clinic
treatment
current
food
drug
administr
fda
approv
therapeut
avail
sever
fdaapprov
drug
includ
select
estrogen
receptor
modul
serm
possess
select
antiebola
activ
howev
inhibitori
mechan
drug
remain
elus
analyz
structur
serm
incident
biolog
activ
cholesterol
accumul
hypothes
incident
biolog
activ
induc
serm
could
plausibl
mechan
inhibitori
effect
ebola
infect
herein
demonstr
dosag
serm
induc
cholesterol
accumul
also
inhibit
ebola
infect
serm
reduc
cellular
sphingosin
subsequ
caus
endolysosom
calcium
accumul
turn
led
block
ebola
entri
studi
clarifi
specif
antiebola
mechan
serm
even
cation
amphiphil
drug
cad
mechan
led
endolysosom
calcium
critic
target
develop
antiebola
drug
ebola
viru
member
filovirida
famili
envelop
rna
viru
caus
hemorrhag
fever
human
nonhuman
primat
speci
depend
lethal
rang
entri
ebola
viru
cell
mainli
mediat
sole
glycoprotein
gp
target
therapeut
intervent
ebola
entri
unusu
requir
proteolyticprim
gp
follow
engag
niemannpick
recent
proven
ebola
viru
enter
cell
endolysosom
contain
twopor
segment
channel
march
recent
ebola
crisi
west
africa
guinea
sierra
leon
libya
reportedli
caus
death
unfortun
still
fdaapprov
vaccin
antiebola
therapeut
consid
timeconsum
process
develop
new
drug
costand
timeeffect
screen
effect
antiebola
drug
among
drug
alreadi
fdaapprov
group
identifi
fdaapprov
drug
select
antiebola
activ
includ
serm
mani
identifi
drug
select
inhibit
infect
ebola
viru
inhibit
vesicular
stomat
viru
vsv
lymphocyt
choriomening
viru
mechan
inhibit
unknown
clear
drug
inhibit
intern
ebola
viru
lysosom
associ
membran
protein
posit
lysosom
acidif
endolysosom
process
ebola
gp
cathepsin
moreov
inhibit
ebola
entri
serm
independ
express
estrogen
receptor
make
mechan
serm
inhibit
ebola
infect
difficult
ascertain
recent
report
toremifen
bind
destabil
ebola
gp
trimer
trigger
prematur
releas
therebi
prevent
fusion
viral
endolysosom
membran
compar
ethyl
chlorin
toremifen
correspond
group
tamoxifen
clomiphen
raloxifen
make
weaker
even
inter
bind
site
ebola
gp
supplementari
fig
howev
tamoxifen
clomiphen
raloxifen
effect
inhibit
ebola
infect
make
interact
ebola
gp
key
mechan
ebola
inhibit
serm
uncertain
mechan
need
studi
interestingli
drug
found
select
antiebola
activ
cad
includ
serm
moreov
sever
studi
show
cad
includ
serm
incident
biolog
activ
ie
druginduc
phospholipidosi
dip
cholesterol
accumul
steatohepat
function
inhibit
acid
sphingomyelinas
asm
acid
ceramidas
ac
much
incident
biolog
activ
cad
relat
structur
properti
sever
cad
weak
base
proton
enter
low
ph
endolysosom
ioniz
form
cad
pass
hydrophob
core
phospholipid
bilay
surround
endolysosom
compart
therefor
trap
concentr
insid
concentr
cad
endolysosom
could
disturb
phospholipid
metabol
transport
lipid
protein
activ
enzym
endolysosom
base
fact
hypothes
incident
biolog
activ
cad
could
plausibl
mechan
observ
inhibit
ebola
infect
studi
explor
relationship
ebola
infect
inhibit
advers
effect
serm
use
lcmsm
assay
imag
endolysosom
calcium
releas
demonstr
serm
could
reduc
cellular
sphingosin
level
subsequ
induc
accumul
endolysosom
calcium
moreov
chelat
lumin
endocyt
calcium
highaffin
rhoddextran
induc
specif
inhibit
ebola
infect
without
inhibit
intern
ebola
viruslik
particl
vlp
endolysosom
data
support
hypothesi
serm
potenti
cad
induc
sphingosin
defect
subsequ
endolysosom
calcium
accumul
turn
inhibit
releas
ebola
endolysosom
serm
select
inhibit
entri
ebola
pseudovirion
estrogen
receptor
pathway
stage
ebola
entri
bind
intern
cell
surfac
well
traffick
fusion
limit
membran
endolysosom
mediat
trimer
gp
spike
array
around
ebola
particl
pseudovirion
model
ebola
gp
simul
stage
wildtyp
ebola
entri
sever
group
studi
ebola
entri
mechan
screen
antiebola
entri
drug
ebola
pseudovirion
model
choos
e
base
ebola
pseudovirion
studi
ebola
entri
ebola
vlpmcherri
compos
gp
studi
ebola
intern
treat
hepatocellular
carcinoma
cell
line
two
serm
tamoxifen
clomiphen
infect
ebola
pseudovirion
serm
select
inhibit
ebola
entri
howev
inhibit
entri
vsv
influenza
wsn
pseudovirion
fig
treatment
estrogen
estrogen
receptor
er
antagonist
inhibit
ebola
pseudovirion
entri
fig
exclud
possibl
serm
inhibit
ebola
entri
er
pathway
determin
effect
serm
ebola
intern
transfect
cell
vector
infect
cell
ebola
vlpmcherri
coloc
vlpmcherri
demonstr
serm
inhibit
ebola
intern
lysosom
rather
block
ebola
vlp
releas
lysosom
fig
report
also
cad
interact
inhibit
also
inhibit
ebola
entri
also
observ
select
inhibit
entri
ebola
pseudovirion
entri
inhibit
observ
vsv
wsn
pseudovirion
inhibit
ebola
vlp
intern
lysosom
supplementari
fig
consid
critic
role
domain
c
ebola
entri
previou
studi
similar
structur
properti
cad
display
select
antiebola
activ
specul
cad
select
antiebola
activ
may
target
inhibit
ebola
entri
test
possibl
express
purifi
domain
c
carri
microscal
thermophoresi
mst
isotherm
titrat
calorimetri
itc
detect
interact
tamoxifen
clomiphen
domain
c
case
detect
interact
mst
itc
supplementari
fig
respect
consid
similar
structur
properti
report
incident
biolog
activ
cad
possibl
incident
biolog
activ
serm
relat
mechan
ebola
entri
inhibit
serm
verifi
hypothesi
compar
effect
serm
dosag
cholesterol
accumul
ebola
entri
inhibit
ebola
pseudovirion
assay
demonstr
serm
inhibit
ebola
entri
start
fig
filipin
stain
also
indic
serm
induc
cholesterol
accumul
approxim
fig
supplementari
fig
therefor
dosag
serm
requir
induc
cholesterol
accumul
match
dosag
serm
requir
ebola
entri
inhibit
impli
incident
biolog
activ
serm
relat
ebola
entri
inhibit
mechan
intriguingli
cholesterol
accumul
appear
h
serm
incub
fig
e
wherea
ebola
viru
alreadi
enter
cytoplasm
approxim
h
thu
specul
intercellular
chang
within
h
serm
treatment
mediat
cholesterol
accumul
inhibit
ebola
entri
effect
e
ici
tamoxifen
clomiphen
ebolawsnvsv
pseudovirion
entri
cell
pretreat
nm
nm
ici
tamoxifen
clomiphen
h
infect
ebolawsnvsv
pseudovirion
compound
h
cell
lyse
luciferas
assay
carri
nh
cl
serv
neg
control
b
repres
imag
coloc
vlp
red
mark
green
mark
egfp
blue
mark
bfp
tamoxifen
clomiphen
treat
white
arrow
indic
exampl
coloc
data
express
mean
sem
n
signific
differ
versu
control
group
present
asterisk
p
p
ns
mean
signific
serm
reduc
cellular
sphingosin
ebola
entri
inhibitor
induc
sphingosin
accumul
within
min
moreov
sphingosin
treatment
also
induc
cholesterol
accumul
specul
serm
may
act
way
induc
accumul
sphingosin
cholesterol
detect
effect
serm
sphingosin
storag
carri
liquid
chromatographytandem
mass
spectrometri
lcmsm
surprisingli
serm
significantli
decreas
sphingosin
hela
cell
line
h
treatment
fig
supplementari
fig
serm
upregul
endolysosom
calcium
level
report
sphingosin
could
regul
level
endolysosom
calcium
demonstr
serm
could
decreas
sphingosin
studi
establish
correl
serm
endolysosom
calcium
imag
glyph
naphthylamid
gpn
sensit
endolysosom
calcium
releas
detect
effect
serm
endolysosom
calcium
level
result
demonstr
serm
significantli
upregul
calcium
releas
gpnsensit
endolysosom
calcium
store
h
treatment
fig
determin
whether
endolysosom
calcium
involv
mechan
ebola
entri
inhibit
treat
cell
line
highaffin
rhoddextran
chelat
intralumin
calcium
infect
cell
ebola
wsn
vsv
pseudovirion
interestingli
chelat
endolysosom
calcium
significantli
specif
inhibit
entri
ebola
inhibitori
effect
observ
vsv
wsn
pseudovirion
fig
chelat
inhibit
intern
ebola
vlp
lysosom
fig
moreov
chelat
endolysosom
calcium
also
induc
cholesterol
accumul
fig
serm
identifi
new
specif
inhibitor
ebola
infect
screen
fda
approv
drug
howev
definit
mechan
serm
inhibit
infect
ebola
still
uncertain
possibl
disturb
acidif
cathepsin
activ
intern
ebola
exclud
previous
attempt
ascertain
relationship
inhibit
ebola
infect
advers
effect
serm
studi
result
indic
tamoxifen
clomiphen
specif
inhibit
releas
ebola
lysosom
inhibit
independ
estrogen
receptor
pathway
entri
ebola
viru
cell
mainli
mediat
sole
glycoprotein
gp
initi
bind
ebola
gp
ctype
lectin
viral
envelop
phosphatidylserin
phosphatidylserin
receptor
ebola
virion
thought
intern
endolysosom
primarili
micropinocytosi
meanwhil
heavili
glycosyl
mucinlik
domain
glycan
cap
remov
low
phdepend
cathepsin
l
b
result
proteolyt
process
gp
expos
receptor
bind
domain
rbd
interact
domain
c
within
endolysosom
interact
domain
c
low
ph
condit
essenti
subsequ
membran
fusion
howev
whether
membran
fusion
trigger
factor
remain
unclear
recent
proven
play
key
role
ebola
viru
infect
ebola
viru
enter
cell
endolysosom
contain
although
definit
role
uncertain
calcium
channel
may
involv
movement
endosom
contain
ebola
viru
membran
fusion
previou
result
demonstr
mediat
entri
ebola
small
molecular
inhibitor
block
infect
ebola
disturb
interact
domain
c
ebola
prime
gp
thu
first
specul
cad
select
antiebola
activ
may
interact
disturb
interact
domain
c
ebola
prime
gp
howev
detect
interact
tamoxifen
domain
c
accord
result
anoth
group
also
show
clomiphen
disturb
interact
domain
c
ebola
prime
gp
recent
studi
demonstr
interact
sterolsens
domain
ssd
inhibit
function
cholesterol
transport
howev
author
emphas
inhibit
ebola
requir
higher
concentr
therefor
exclud
possibl
interact
ssd
inhibit
ebola
entri
thu
data
demonstr
target
cad
ebola
entri
inhibit
approxim
fda
approv
drug
shown
select
antiebola
activ
structur
analysi
reveal
drug
cad
supplementari
tabl
major
cad
select
antiebola
activ
similar
structur
properti
pka
logp
supplementari
fig
base
structur
properti
cad
proton
trap
final
concentr
acid
endolysosom
compart
due
liposolubl
cad
insert
lipid
bilay
endolysosom
disturb
metabol
lipid
transport
sever
compon
lead
dip
cholesterol
accumul
andor
function
inhibit
asm
supplementari
fig
moreov
cad
induc
incident
biolog
activ
micromolar
concentr
match
concentr
inhibit
ebola
infect
cad
thu
possibl
cad
inhibit
ebola
entri
incident
biolog
activ
filipin
stain
ebola
pseudovirion
entri
assay
demonstr
serm
induc
cholesterol
accumul
inhibit
ebola
entri
concentr
approxim
howev
cholesterol
accumul
h
appear
ebola
entri
cytoplasm
h
impli
someth
chang
within
h
serm
treatment
mediat
cholesterol
accumul
inhibit
ebola
entri
contrast
previou
report
data
demonstr
serm
decreas
sphingosin
within
h
discrep
might
due
differ
cell
type
andor
differ
treatment
dosag
use
agreement
result
much
research
demonstr
cad
induc
detach
asm
protein
inner
endolysosom
membran
lead
inactiv
sever
cad
identifi
function
inhibitor
asm
elojeimi
et
al
demonstr
cad
also
inhibit
activ
ac
due
metabol
pathway
sphingomyelin
inhibit
asm
ac
decreas
cellular
sphingosin
report
ebola
infect
requir
asm
activ
cad
could
inhibit
ebola
entri
inhibit
asm
activ
howev
asm
involv
ebola
infect
still
unknown
futur
studi
need
better
understand
molecular
mechan
asm
ebola
entri
well
known
intracellular
calcium
signal
involv
vesicular
fusion
whether
fusion
ebola
endolysosom
membran
also
requir
calcium
signal
still
unclear
vitro
conform
chang
membranebound
ebola
fusion
peptid
requir
vesicl
fusion
depend
calcium
concentr
moreov
protein
endolysosom
calcium
channel
recent
identifi
key
player
ebola
entri
inhibitor
tpc
block
nicotin
acid
adenin
dinucleotid
phosphat
naadp
stimul
calcium
outflow
ebola
infect
sphingosin
treatment
could
induc
deregul
endolysosom
calcium
subsequ
studi
demonstr
mainli
mediat
endolysosom
calcium
respons
sphingosin
consist
result
prove
serm
decreas
sphingosin
increas
endolysosom
calcium
addit
chelat
lumin
endocyt
calcium
highaffin
rhoddextran
also
block
ebola
infect
intern
ebola
vlp
lysosom
taken
togeth
result
demonstr
endolysosom
calcium
involv
ebola
infect
also
possibl
involv
ebolaendolysosom
membran
fusion
event
recent
zhao
et
al
report
toremifen
bind
destabil
ebola
gp
trimer
trigger
prematur
releas
therebi
prevent
fusion
viral
endolysosom
membran
studi
reveal
mechan
ebola
inhibit
toremifen
howev
bind
destabil
gp
may
play
major
role
situat
firstli
author
inform
residu
line
bind
site
highli
conserv
among
filovirus
except
marburg
viru
marv
suggest
marv
may
bind
drug
proven
toremifen
clomiphen
even
cad
could
effect
inhibit
infect
marv
secondli
compar
ethyl
chlorin
toremifen
correspond
ethyl
group
tamoxifen
chlorin
clomiphen
make
weaker
inter
bind
site
ebola
gp
obviou
structur
differ
raloxifen
cad
antiebola
activ
toremifen
make
interact
weaker
supplementari
fig
howev
drug
effect
inhibit
ebola
infect
thirdli
mani
cad
antiebola
activ
inhibit
ebola
andor
marv
infect
similar
kinet
inhibit
hard
explain
interact
gp
therefor
bind
gp
play
major
role
ebola
inhibit
toremifen
may
ebola
marv
inhibit
toremifen
tamoxifen
clomiphen
raloxifen
even
cad
antiebola
activ
studi
demonstr
serm
inhibit
ebola
pseudovion
entri
induc
cholesterol
accumul
equal
dosag
reduc
cellular
sphingosin
upregul
endolysosom
calcium
level
regul
sphingosin
moreov
chelat
endolysosom
calcium
significantli
specif
inhibit
entri
ebola
base
previou
studi
result
propos
hypothesi
ebola
infect
fig
normal
condit
ebola
intern
endolysosom
prime
gp
interact
domain
c
asm
ac
endolysosom
hydrolyz
sphingomyelin
sphingosin
elev
sphingosin
induc
endolysosom
calcium
outflow
local
calcium
flux
interact
prime
gp
domain
c
induc
conform
chang
ebola
fusion
peptid
trigger
membran
fusion
ebola
infect
treat
cad
select
antiebola
activ
includ
serm
cad
proton
trap
insid
acid
endolysosom
due
structur
properti
concentr
cad
induc
detach
asm
protein
membran
inactiv
asm
turn
lead
decreas
sphingosin
reagent
estradiol
e
ici
ici
er
antagonist
tamoxifen
clomiphen
citrat
filipin
purchas
sigmaaldrich
sigma
us
derythrosphingosin
sph
purchas
avanti
polar
lipid
alabastar
us
highaffin
strong
calcium
buffer
rhoddextran
purchas
thermo
fisher
life
technolog
us
dmso
sigma
us
use
solvent
tamoxifen
clomiphen
citrat
pb
use
highaffin
rhoddextran
methanol
sigma
us
use
sph
cell
plasmid
human
hepatoma
cell
line
hela
cervic
carcinoma
cell
line
human
embryon
kidney
hek
cell
line
obtain
cell
resourc
center
peke
union
medic
colleg
licens
atcc
maintain
eagl
minimum
essenti
medium
gibco
invitrogen
us
hela
maintain
dulbecco
modifi
eagl
medium
high
glucos
dmemhg
gibco
invitrogen
us
supplement
fb
gibco
invitrogen
us
uml
penicillin
sigma
us
gml
streptomycin
sigma
us
cell
cultur
humidifi
atmospher
co
ebola
guecked
strain
gp
ebola
vsv
gp
wsn
hana
e
vector
gener
describ
previous
delet
mucin
ebola
gp
overlappcr
reduc
cytotox
ebola
gp
express
vector
construct
insert
vector
express
purif
c
domain
domain
c
construct
express
purifi
previous
describ
briefli
cell
infect
domain
baculoviru
use
infect
cell
incub
h
cell
pellet
centrifug
medium
concentr
tangenti
flow
filtrat
concentr
medium
appli
ninta
column
fraction
contain
pool
concentr
concentr
appli
superdex
gel
filtrat
column
cdna
encod
domain
c
clone
vector
domain
c
express
escherichia
coli
strain
inclus
bodi
refold
vitro
use
method
previous
describ
refold
concentr
purifi
gel
filtrat
hiload
superdex
pg
column
ge
healthcar
itc
experi
carri
instrument
microc
us
sampl
cell
contain
domain
c
tamoxifenclomiphen
compound
ad
inject
l
data
process
use
origin
softwar
microc
us
experi
duplic
three
time
microscal
thermophoresi
affin
measur
use
mst
carri
monolith
instrument
nanotemp
technolog
germani
domain
label
use
nanotemp
nh
label
kit
nanotemp
technolog
germani
label
reaction
perform
accord
manufactur
instruct
appli
final
concentr
protein
molar
excess
dye
rt
min
dark
free
dye
elimin
use
suppli
dyeremov
column
equilibr
domain
storag
buffer
tamoxifen
clomiphen
dilut
domain
storag
buffer
creat
dilut
seri
dilut
nm
tamoxifen
clomiphen
nm
thermophoresi
experi
ligand
dilut
mix
label
domain
incub
min
rt
appli
sampl
monolith
nt
standard
treat
capillari
nanotemp
technolog
germani
thermophoresi
measur
rt
led
power
mst
irlas
power
data
least
three
independ
perform
experi
analyz
nt
analysi
softwar
version
nanotemp
technolog
germani
use
signal
thermophoresi
tjump
experi
duplic
three
time
ebola
entri
traffick
assay
ebola
pseudovirion
vlp
prepar
transfect
hek
cell
use
polyethylenimin
four
plasmid
codonoptim
mucin
ebola
guecked
strain
gp
hiv
base
e
ebola
pseudovirion
ebola
gp
ebola
ebola
mcherri
fuse
n
terminu
ebola
vlp
plasmid
transfect
ratio
respect
vsv
wsn
pseudovirion
gener
ident
fashion
substitut
plasmid
encod
vsv
gp
wsn
hana
cultur
supernat
hour
posttransfect
hpt
collect
replac
fresh
media
second
harvest
conduct
hpt
harvest
pool
clear
cell
debri
two
sequenti
centrifug
g
min
vlp
clear
supernat
pellet
sucros
mm
hepe
mm
nacl
ph
hnb
g
rpm
rotor
hour
pellet
vlp
resuspend
overnight
sucros
hnb
origin
volum
cultur
medium
collect
aliquot
store
approxim
h
experi
cell
plate
well
dish
cell
pretreat
min
indic
concentr
inhibitor
dmso
vehicl
medium
without
fb
drug
concentr
maintain
subsequ
step
experi
lysi
preincub
period
cell
infect
l
ebola
pseudovirion
h
lyse
luciferas
assay
accord
manufactur
instruct
galen
china
ebola
traffick
assay
cell
transfect
plasmid
use
lipofectamin
invitrogen
us
hpt
cell
pretreat
dmso
tamoxifen
clomiphen
h
cell
incub
ebola
vlp
h
fix
cell
mount
imag
nikon
confoc
microscop
system
nikon
japan
filipin
stain
cholesterol
accumul
monitor
stain
cell
filipin
day
experi
cell
plate
glass
coverslip
plate
next
day
cell
treat
inhibitor
indic
concentr
h
fixat
paraformaldehyd
cell
wash
twice
pb
incub
mgml
filipin
sigma
us
pb
h
wash
time
pb
coverslip
mount
imag
zeiss
axio
observ
fluoresc
microscop
carl
zeiss
germani
repres
imag
invert
clariti
shown
uniform
adjust
bright
contrast
across
imag
sphingosin
measur
perform
sphingosin
measur
use
lcmsm
thermo
us
previous
describ
briefli
cell
wash
twice
icecold
pb
cell
pellet
contain
approxim
cell
harvest
scrape
cell
icecold
pb
transfer
prechil
ml
new
eppendorf
tube
ice
suspend
cell
centrifug
rpm
min
remov
pb
cell
pellet
resuspend
l
distil
water
sampl
prepar
cell
pellet
store
use
l
cell
suspens
l
intern
standard
ngml
l
methanol
ad
ml
eppendorf
tube
mixtur
vortexmix
follow
centrifug
rpm
min
supernat
transfer
clean
glass
vial
l
supernat
inject
lcmsm
system
analysi
autosampl
set
endolysosom
calcium
assay
endolysosom
calcium
assay
carri
previous
describ
modif
cell
preincub
tamoxifen
clomiphen
h
load
membraneperm
calcium
indic
abcam
us
min
room
scientif
report
doi
temperatur
place
calciumfre
buffer
confoc
live
imag
repeat
two
differ
roi
treatment
thapsigargin
tg
sigma
us
load
releas
endoplasm
reticulum
calcium
glyph
naphthylamid
gpn
sigma
us
load
releas
acid
compart
endolysosom
calcium
gpn
induc
calcium
releas
quantifi
imag
j
softwar
version
imag
process
analysi
java
nih
bethesda
md
http
rsbinfonihgovijdownloadhtml
statist
analysi
data
analyz
statist
signific
spss
packag
spss
inc
us
data
group
first
test
normal
shapirowilk
test
group
data
normal
distribut
compar
use
oneway
analysi
varianc
p
valu
regard
statist
signific
valu
present
mean
sem
standard
error
mean
graph
gener
graphpad
prism
graphpad
softwar
inc
us
